ATLANTA, GA – – (Globe Newswire – November 12, 2025) – – A shareholder class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (“Telix”) (NASDAQ: TLX). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Telix’s business, operations, and prospects, including allegations that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased shares of Telix between February 21, 2025 and August 28, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/telix-pharmaceuticals/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is January 9, 2026.